Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study.

Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations.

Key topics discussed include:

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment.

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]